Agnholt Jørgen
Arhus Universitetshospital, Arhus Sygehus, Medicinsk Hepato-gastroenterologisk Afdeling V, Arhus C.
Ugeskr Laeger. 2008 Jun 9;170(24):2152-6.
Biological therapy as treatment of inflammatory bowel diseases has been one of the major achievements since the introduction of steroids. Infliximab has been approved for the treatment of Crohn's disease and ulcerative colitis, and adalimumab for the treatment of Crohn's disease. Both treatments have documented effect for induction of clinical response and remission, and can be used to maintain remission. However, it is important to define the treatment goals before initiation, and whether biologicals should be used alone or together with immunosuppressants as azathioprine.
自类固醇药物问世以来，生物疗法作为炎症性肠病的治疗方法一直是主要成就之一。英夫利昔单抗已被批准用于治疗克罗恩病和溃疡性结肠炎，阿达木单抗用于治疗克罗恩病。这两种治疗方法都已证明对诱导临床反应和缓解有效，并且可用于维持缓解状态。然而，在开始治疗前明确治疗目标以及生物制剂应单独使用还是与硫唑嘌呤等免疫抑制剂联合使用很重要。
